argenx SE Announces Annual General Meeting
Ticker: ARGX · Form: 6-K · Filed: Apr 14, 2025 · CIK: 1697862
Sentiment: neutral
Topics: agm, corporate-governance, biotech
TL;DR
argenx SE holding its annual meeting, standard corporate stuff.
AI Summary
On April 11, 2025, argenx SE announced its upcoming annual general meeting. The company, a biopharmaceutical firm focused on autoimmune diseases, is based in Zwijnaarde, Belgium, and is registered in the Netherlands. This filing is a routine report of foreign private issuer information.
Why It Matters
This filing signals routine corporate governance activities for argenx SE, a key player in the biopharmaceutical sector.
Risk Assessment
Risk Level: low — The filing is a routine announcement of an annual general meeting, not indicating any immediate financial or operational risks.
Key Players & Entities
- argenx SE (company) — Registrant
- April 11, 2025 (date) — Date of press release
- Zwijnaarde, Belgium (location) — Company's business address
- Amsterdam, the Netherlands (location) — Company's principal executive offices
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report that argenx SE issued a press release on April 11, 2025, announcing its annual general meeting.
What is the filing date of this report?
This report was filed as of April 14, 2025.
What is the company's principal executive office location?
The company's principal executive offices are located at Laarderhoogtweg 25, 1101 EB Amsterdam, the Netherlands.
What is argenx SE's business address?
argenx SE's business address is Industriepark Zwijnaarde 7, Building C, B-9052 Zwijnaarde, Belgium.
Under which SEC Act is this report filed?
This report is filed under the Securities Exchange Act of 1934, pursuant to Rule 13a-16 or 15d-16.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 14, 2025 regarding ARGENX SE (ARGX).